“With the antiviral pill, Merck hopefully can take what ... be available in the market by late this year. The US government has promised to purchase 1.7 million courses of treatment at $700 ...
While the US government is paying $712 per treatment course, Merck is allowing generic manufacturers to make its pill for lower-income markets, where they will likely charge a fraction of that cost.
Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year ... the U.S. government agreed to buy molnupiravir if the FDA recommends ...
The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA. The $1.2 billion ...
But US authorities recently made an advance purchase of 1.7 million ... also made purchase agreements. Merck is the first company to report trial results of a pill to treat Covid, but other ...
On Nov 4, Britain was the first country in the world to approve the potential antiviral pill developed jointly by Merck & Co Inc and Ridgeback Biotherapeutics, both based in the US. Molnupiravir ...
The company paid US$200 per share, more than 70% above the Prometheus's closing share price on April 14, before the acquisition was announced on April 16. The majority of the offering contains special ...
Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Merck Animal Health, Richard DeLuca, for US$4.6m worth ... insiders didn't buy any shares ...
The company paid US$200 per share, more than 70% above the Prometheus's closing share price on April 14, before the acquisition was announced on April 16. The majority of the offering contains special ...